CoChat

Immune Responses to AAV Capsid: Are Mice Not Humans After All?

Open access
Herzog, Roland W · 2007 · Molecular Therapy
Cited by 56

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

See page 792Adeno-associated viruses (AAVs) have been favored for in vivo gene transfer of therapeutic genes because of their low immunogenicity, strong safety record, and high efficiency of transduction of a number of cell types in animal models.1Wu Z Asokan A Samulski RJ Adeno-associated virus serotypes: vector toolkit for human gene therapy.Mol Ther. 2006; 14: 316-327Abstract Full Text Full Text PDF PubMed Scopus (618) Google Scholar However, in a recent gene therapy trial involving delivery of human coagulation factor IX (F.IX) for the treatment of hemophilia, two patients developed a T-cell response to AAV-2 capsid, which was not predicted from preclinical studies in animals. Importantly, transgene expression in the two patients declined to pretreatment levels, suggesting that a cytotoxic T-lymphocyte (CTL) response to the capsid may have been responsible for a loss of transgene-expressing cells. In this issue, Li et al. now provide a detailed analysis of the effect of CTL responses to AAV capsid in mice.2Li H Murphy SL Giles-Davis W Edmonson S Xiang Z Li Y et al.Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.Mol Ther. 2007; 15: 792-800Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar The results highlight a problem facing the field: the lack of an appropriate and predictive animal model for immune-mediated loss of hepatocytes after transduction with AAV.Enthusiasm for the AAV vector system grew tremendously approximately a decade ago, when several laboratories demonstrated sustained expression of a bacterial LacZ gene without activation of CTLs after intramuscular injection of recombinant AAV (serotype 2).3Fisher KJ Jooss K Alston J Yang Y Haecker SE High K et al.Recombinant adeno-associated virus for muscle directed gene therapy.Nat Med. 1997; 3: 306-312Crossref PubMed Scopus (574) Google Scholar,4Kessler PD Podsakoff GM Chen X McQuiston SA Colosi PC Matelis LA et al.Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.Proc Natl Acad Sci USA. 1996; 93: 14082-14087Crossref PubMed Scopus (533) Google Scholar,5Xiao X Li J Samulski RJ Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.J Virol. 1996; 70: 8098-8108Crossref PubMed Google Scholar Similarly, T-cell responses and innate responses to AAV capsid were consistently low in animal studies. In other experiments, sustained expression of a F.IX gene over several years in animal models of the X-linked bleeding disorder, hemophilia B, has been documented for muscle- and liver-directed gene transfer.6Herzog RW Yang EY Couto LB Hagstrom JN Elwell D Fields PA et al.Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.Nat Med. 1999; 5: 56-63Crossref PubMed Scopus (468) Google Scholar,7Snyder RO Miao C Meuse L Tubb J Donahue BA Lin HF et al.Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.Nat Med. 1999; 5: 64-70Crossref PubMed Scopus (314) Google Scholar These observations led to two phase I/II clinical trials. In the muscle-directed approach, gene transfer was long lasting and safe but subtherapeutic.8Manno CS Chew AJ Hutchison S Larson PJ Herzog RW Arruda VR et al.AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.Blood. 2003; 101: 2963-2972Crossref PubMed Scopus (593) Google ScholarA major concern in gene therapy for hemophilia is the risk of antibody formation to the coagulation factor transgene product. Therefore, subjects enrolled in the muscle trial were limited to those with F.IX missense mutations. Interestingly, liver-directed gene transfer showed higher efficacy than intramuscular injection, and the hepatic route was found to induce immune tolerance to F.IX and other transgene products.9Mingozzi F Liu YL Dobrzynski E Kaufhold A Liu JH Wang Y et al.Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.J Clin Invest. 2003; 111: 1347-1356Crossref PubMed Scopus (371) Google Scholar Consequently, hopes were high for the liver trial, and the only major immunological concern was that preexisting immunity in the form of neutralizing antibodies might prevent gene transfer, because most humans are seropositive for AAV-2. As predicted from studies in large animals, the first human subject with low preexisting neutralizing antibodies in the highest vector dose cohort exhibited therapeutic F.IX expression (>10%) after infusion of the AAV-2 vector into the hepatic artery.10Manno CS Pierce GF Arruda VR Glader B Ragni M Rasko JJ et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.Nat Med. 2006; 12: 342-347Crossref PubMed Scopus (1534) Google Scholar However, F.IX activity declined to pretreatment l

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.mt.6300123

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 56

Metadata

Authors
Herzog, R. W.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2007-04
Volume
15
Issue
4
Pages
649-650
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2020030124
Cited by
56
References
7
FWCI
2.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Responses to AAV Capsid: Are Mice Not Humans After All? https://app.cochat.ai/papers/10.1038/sj.mt.6300123
The paper
Herzog, R. W. (2007). Immune Responses to AAV Capsid: Are Mice Not Humans After All? Molecular Therapy. https://doi.org/10.1038/sj.mt.6300123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.